



FORM PTO-1449 (Modified)

MAY 1 0 2001

Attorney Docket No.: 15280-317100US

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE & TRADEMARK
STATEMENT (Use several sheets if necessary)**

Applicant: FitzGerald et al.

Filing Date: September 20, 1999

Application No.: 09/381,497

Reference Designation

U.S. PATENT DOCUMENTS

Page 1

RECEIVED

MAY 15 200

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----------|--|
| AB | J. DE KRUIF ET AL.: "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes." FEBS LETTERS, vol. 399, no. 3, 16 December 1996, pages 232-236, XP002075140 Amsterdam, NL |
| AC | D. LUO ET AL.: "V1-linker-Vh orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions." JOURNAL OF BIOCHEMISTRY, vol. 118, NO. 4, 1 October 1995, pages 825-831, XP002075145 Tokyo, Japan |
| AD | E. MANSFIELD ET AL.: "Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies." BIOCONJUGATE CHEMISTRY, vol. 7, no. 5, September 1996, pages 557-563, XP002075147 Washington, DC, USA |
| AE | E. MANSFIELD ET AL.: "Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors." BLOOD, vol. 90, no. 5, 1 September 1997, pages 2020-2026, XP002075148 New York, NY, USA |
| AF | V. RAJAGOPAL ET AL.: "A form of anti-Tac(Fv) which is both single-chain and disulfide-stabilized for imaging CD25+ tumors." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 8, March 1997, page 27 XP002075144 USA see abstract #180 |
| AG | M. RODRIGUES ET AL.: "Development of a humanized disulfide-stabilized anti-p185HER2 Fv-betalactamase fusion protein for activation of a cephalosporin doxorubicin prodrug." CANCER RESEARCH, vol. 55, NO. 1, 1 January 1995, pages 63-70, XP002075146 Baltimore, MD, USA |
| EXAMINER | DATE CONSIDERED |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.